Zobrazeno 1 - 10
of 522
pro vyhledávání: ''
Publikováno v:
Clinical Lung Cancer. 23:e118-e130
To evaluate postoperative outcome and quality of life (QOL), comparing patients80 years old to patients ≥ 80.EORTC questionnaires, QLQ-C30 and QLQ-LC13 was used to assess QOL, in patients after surgery. Results were evaluated according to 3 age gro
Autor:
Xingpeng Han, Yin Li, Jian Hu, Yang Liu, Xiangning Fu, Xin Peng, Xiaofei Li, Tianyu He, Lunxu Liu, Heng Zhao, Yihe Wu, Jinming Xu, Deruo Liu, Lin Xu, Jinlin Cao
Publikováno v:
Clinical Lung Cancer. 23:170-176
Background Video-assisted thoracic surgery (VATS) has been widely used in the surgical treatment of thoracic diseases, and it suggested surgical and oncological advantages compared with open surgery. However, reports on the application of VATS in sur
Autor:
Hee Soon Juon, Marcella Pimpinelli, Brooke Ruane, Charnita Zeigler-Johnson, Russell K. McIntire, Christine S. Shusted, Julie A. Barta, Gregory C. Kane, Nathaniel R. Evans, Ronald E. Myers
Publikováno v:
Clinical Lung Cancer. 22:570-578
One challenge in high-quality lung cancer screening (LCS) is maintaining adherence with annual and short-interval follow-up screens among high-risk individuals who have undergone baseline low-dose CT (LDCT). This study aimed to characterize attitudes
Autor:
Yuan Wu, Chester Kao, Tian Zhang, Neal Ready, Michael B. Datto, Eric Powers, Jeffrey M. Clarke, John H. Strickler, Michelle F. Green
Publikováno v:
Clinical Lung Cancer. 22:500-509
Introduction A high tumor mutational burden (TMB) (≥10 mut/Mb) has been associated with improved clinical benefit in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI) and is a tumor agnostic indication for pembroliz
Autor:
Cristina Merkhofer, Renato G. Martins, Scott D. Ramsey, Keith D. Eaton, Bernardo H. L. Goulart
Publikováno v:
Clin Lung Cancer
Introduction The impact of clinical trial participation on overall survival is unclear. We hypothesized that enrollment in a therapeutic drug clinical trial is associated with longer overall survival in patients with metastatic non-small cell lung ca
Publikováno v:
Clinical Lung Cancer. 22:e901-e910
Introduction While guidelines recommend testing for actionable biomarkers for patients with advanced or metastatic NSCLC, testing rates have varied. This study aimed to assess molecular testing patterns in a large network of US community-based oncolo
Publikováno v:
Clinical Lung Cancer. 22:e808-e816
Background Conflicting data exists regarding the benefit of prophylactic cranial irradiation (PCI) in patients with extensive-stage small-cell lung cancer (ES-SCLC). We sought to retrospectively review outcomes of patients within our network with ES-
Autor:
Yohei Masugi, Hirokazu Matsushita, Hiroaki Kuroda, Yusuke Takahashi, Takao Shigenobu, Ryutaro Hanawa, Atsushi Tajima
Publikováno v:
Clinical Lung Cancer. 22:e820-e828
Histologic subtyping offers some prognostic value in lung adenocarcinoma. We thus hypothesized that histologic subtypes may be useful for risk stratification of brain metastasis (BM). In this study, we aimed to investigate the impact of histologic su
Autor:
Annapaola Mariniello, Simona Carnio, Cristina Cecchi, Silvia Novello, Marco Donatello Delcuratolo
Publikováno v:
Clinical Lung Cancer. 22:e804-e807
Clinical Practice Points • Immune checkpoint inhibitors (ICIs) are associated with the development of unique immune-related adverse events (irAEs), which emerged primarily during post-marketing surveillance. Oral irAEs have already been reported, w
Autor:
Xavier Quantin, Nicolas Girard, Marylise Ginoux, Luc Thiberville, Benjamin Besse, Christelle Clément-Duchêne, P.A. Thomas, P. Mordant, Angela Botticella, C. Le Pechoux, J. Khalifa, Eric Pichon, Thierry Jo Molina, F. Le Tinier, Youssef Oulkhouir, Mallorie Kerjouan, Clémence Basse, Pierre Emmanuel Falcoz, F. Thillays, Virginie Westeel
Publikováno v:
Clinical Lung Cancer
Clinical Lung Cancer, Elsevier, 2021, ⟨10.1016/j.cllc.2021.01.020⟩
Clinical Lung Cancer, Elsevier, 2021, ⟨10.1016/j.cllc.2021.01.020⟩
Introduction Thymomas are rare intrathoracic malignancies that may be aggressive and difficult to treat. Knowledge and level of evidence for treatment strategies are mainly based on retrospective studies or expert opinion. Currently there is no stron